iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Business Wire
PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for severe inherited neurometabolic disorders, today announced that clinical data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 in neonatal-onset ornithine transcarbamylase (OTC) deficiency will be presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026 in Boston, and the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, taking place May 17-20, 2026 in Puerto Rico.The oral presentation at ASGCT will include preliminary data from study participants in the first three dose cohorts (n=7) of the OTC-HOPE study, including a decreased rate of hyperammonemic crises (HAC) following ECUR-506 administration. HACs represent the most serious and life-threatening manifestation of OTC deficiency, and reductions in these events are considered a clinically meani
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026Business Wire
- Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD StudyBusiness Wire
- Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual MeetingBusiness Wire
- Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business Wire
DTIL
Earnings
- 3/12/26 - Beat
DTIL
Sec Filings
- 4/15/26 - Form SCHEDULE
- 4/8/26 - Form ARS
- 4/8/26 - Form DEFA14A
- DTIL's page on the SEC website